portfolio
team
news
| Oct 26, 2011 |
Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures
FierceMedicalDevices, USA
Invuity, a leading developer of state-of-the-art illuminated surgical technology, today introduced its illuminated breast retractor system at the American College of Surgeons' 97th Annual Clinical Congress in San Francisco
more >>
|
| Oct 18, 2011 |
iScience Interventional Announces Clinical and Commercial Supply Agreement
iScience Interventional, Menlo Park, CA
iScience Interventional pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates.
more >>
|
| Feb 16, 2011 |
Chimerix Awarded BARDA Contract for Advanced Development of Antiviral CMX001 as Medical Countermeasure Against Smallpox
Chimerix, Inc., Durham, North Carolina
Chimerix, Inc. has been awarded a contract that will finance the smallpox drug development with committed funding of $24.8 million during the first year and subsequent option to bring the total contract value to $81.1 million.
more >>
|
| Feb 11, 2011 |
Sonoma Orthopedic Products® Announces Acquisition of Key NovaLignTM Orthopaedics, Inc. Assets
Sonoma Orthopedic Products, Inc., Santa Rosa, California
Sonoma Orthopedic Products announced that it has completed the acquisition of certain key assets of NovaLign Orthopaedics, Inc.
more >>
|
| Apr 09, 2010 |
Innovation, by Order of the Kremlin
The New York Times, New York, United States
Dr. Evgeny Zaytsev answers questions by Andrew Kramer, The New York Times correspondent, on the Russian initiative to build an
more >>
|
| Mar 09, 2010 |
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus.
Chimerix, Inc., Durham, North Carolina
Chimerix announces a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients seropositive for cytomegalovirus (CMV).
more >>
|
| Jan 14, 2010 |
Pills Get Smart. Potential Encapsulated.
Economist, New York, United States
Article about the business potential of just announced licensing deal between Proteus Biomedical and Novartis.
more >>
|
| Sep 29, 2009 |
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive safety data for for a new Type 2 Diabetes treatment.
more >>
|
| Sep 29, 2009 |
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive Phase IIb data for a new Type 2 Diabetes treatment with superior safety profile.
more >>
|
| Sep 20, 2009 |
Novartis chip to help ensure bitter pills are swallowed
Financial Times, London, UK
Article on possible Novartis collaboration with Proteus Biomedical to improve patient adherence.
more >>
|
| Aug 03, 2009 |
Take Two Digital Pills and Call Me in the Morning
The Wall Street Journal, United States
WSJ reporter Don Clark presents Proteus Biomedical’s intelligent medicine platform.
more >>
|
| May 30, 2009 |
New breast cancer drugs block cell repair enzyme
Reuters, United States
BiPar Sciences presents positive Phase II data at the annual meeting of the American Society of Clinical Oncology meeting.
more >>
|
| May 18, 2009 |
Emergency IND granted for the use of CMX001 to treat complications following smallpox vaccination
CDC, Atlanta, United States
CMX001, a drug developed by Chimerix, Inc. proves effective in an emergency case.
more >>
|
| May 12, 2009 |
Canaloplasty 2-year clinical results published
Ophthalmology Times, United States
iScience Interventional’s 2-year data confirm sustained eye pressure drop.
more >>
|
| Apr 15, 2009 |
BiPar Buyout Proves VC Model Can Work
The Wall Street Journal, United States
WSJ reporter Brian Gormley interviews Dr. Graham Crooke on the BiPar investment model.
more >>
|